Press Release 16 Sep 2024 Autobahn Therapeutics Announces Initiation of its AMPLIFY Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Major Depressive Disorder by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics Completes Oversubscribed $100 Million Series C Financing to Advance Pipeline of Novel Therapeutics for Depression and Other CNS Disorders by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics to Participate in the Leerink Partners Biopharma Private Company Connect by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics to Participate in the Jefferies Global Healthcare Conference by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics to Present at the Stifel 2024 Virtual CNS Days by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics to Participate in Upcoming Investor Conferences by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics to Present at the Stifel 2023 Healthcare Conference by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics Announces Positive Topline Results from Phase 1 Study of ABX-002, its Lead Oral Treatment for Major Depressive Disorder by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics to Present at Upcoming Investor Conferences by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics Completes Dosing in its Phase 1 Multiple-ascending Dose Study of ABX-002 for Major Depressive Disorder and Reports Company Progress by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics Advances ABX-002, its Lead Oral Treatment for Major Depressive Disorder, into Multi-Ascending Dose Portion of Phase 1 Trial by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics to Present at the Stifel 2023 Virtual CNS Days by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics Announces Initiation of a Phase 1 Clinical Trial of ABX-002 for the Treatment for Major Depressive Disorder by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics Announces Successful Financing to Support Strategic Advancement of ABX-002 for Treatment Resistant Depression by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics Announces Emerging Preclinical Data Demonstrating Ability of CNS-Delivered Thyromimetics to Promote Remyelination by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics to Present New Preclinical Data at the 2022 American Academy of Neurology Annual Meeting by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics Announces New Preclinical Data Supporting its Novel Brain-Targeting Platform for the Development of Therapeutics for CNS Disorders by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics Strengthens Management Team to Support Advancement of Novel Therapies for CNS Disorders by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics Acquires Clinical-Stage FAAH Inhibitor from Astellas, Strengthening its Brain Targeting Chemistry Platform by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics Presents Preclinical, Proof of Concept Data for ABX-002 for the Treatment of Adrenomyeloneuropathy by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 ARCH-backed Autobahn launches with $76M to rebuild myelin and reverse MS by Autobahn Therapeutics Read More
Press Release 16 Sep 2024 Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders by Autobahn Therapeutics Read More